As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
10 Analysts have issued a Heron Therapeutics Inc forecast:
10 Analysts have issued a Heron Therapeutics Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 150 150 |
10%
10%
|
|
| Gross Profit | 112 112 |
25%
25%
|
|
| EBITDA | 2.36 2.36 |
105%
105%
|
|
| EBIT (Operating Income) EBIT | 0.03 0.03 |
100%
100%
|
|
| Net Profit | -0.93 -0.93 |
98%
98%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.
| Head office | United States |
| CEO | Craig Collard |
| Employees | 122 |
| Founded | 1983 |
| Website | www.herontx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


